China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
- Written by PR Newswire
SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeutic signals in solid tumors, and good safety...
Read more: China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released